Analysts Anticipate Spring Bank Pharmaceuticals Inc (SBPH) Will Announce Earnings of -$0.50 Per Share

Share on StockTwits

Wall Street brokerages expect Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) to announce ($0.50) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Spring Bank Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.49). Spring Bank Pharmaceuticals reported earnings per share of ($0.47) during the same quarter last year, which suggests a negative year over year growth rate of 6.4%. The company is scheduled to report its next quarterly earnings results on Tuesday, February 19th.

On average, analysts expect that Spring Bank Pharmaceuticals will report full year earnings of ($1.76) per share for the current fiscal year, with EPS estimates ranging from ($1.89) to ($1.53). For the next year, analysts anticipate that the company will post earnings of ($2.26) per share, with EPS estimates ranging from ($2.67) to ($1.90). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Spring Bank Pharmaceuticals.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last issued its quarterly earnings data on Thursday, October 25th. The company reported ($0.51) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.01.

A number of research analysts recently commented on the company. Cantor Fitzgerald set a $35.00 price objective on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Jefferies Financial Group assumed coverage on Spring Bank Pharmaceuticals in a research note on Tuesday, October 9th. They set a “buy” rating and a $28.00 price objective for the company. Piper Jaffray Companies assumed coverage on Spring Bank Pharmaceuticals in a research note on Tuesday, August 14th. They set an “overweight” rating and a $25.00 price objective for the company. Finally, Chardan Capital restated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Sunday, October 28th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $29.00.

In related news, insider Martin J. Driscoll acquired 4,000 shares of the stock in a transaction that occurred on Monday, August 13th. The stock was purchased at an average cost of $12.02 per share, for a total transaction of $48,080.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 15.60% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the business. Jennison Associates LLC acquired a new position in Spring Bank Pharmaceuticals during the 3rd quarter worth $8,210,000. BlackRock Inc. boosted its position in Spring Bank Pharmaceuticals by 25.0% during the 3rd quarter. BlackRock Inc. now owns 604,067 shares of the company’s stock worth $7,279,000 after acquiring an additional 120,809 shares during the period. Morse Asset Management Inc boosted its position in Spring Bank Pharmaceuticals by 7.1% during the 3rd quarter. Morse Asset Management Inc now owns 190,050 shares of the company’s stock worth $2,290,000 after acquiring an additional 12,550 shares during the period. Millennium Management LLC boosted its position in Spring Bank Pharmaceuticals by 82.3% during the 1st quarter. Millennium Management LLC now owns 91,663 shares of the company’s stock worth $1,410,000 after acquiring an additional 41,372 shares during the period. Finally, C WorldWide Group Holding A S boosted its position in Spring Bank Pharmaceuticals by 4.9% during the 2nd quarter. C WorldWide Group Holding A S now owns 91,567 shares of the company’s stock worth $1,085,000 after acquiring an additional 4,245 shares during the period. Institutional investors own 27.11% of the company’s stock.

SBPH traded down $0.60 during trading on Friday, reaching $11.18. 70,094 shares of the company were exchanged, compared to its average volume of 58,679. The company has a market cap of $194.08 million, a P/E ratio of -5.98 and a beta of 0.89. Spring Bank Pharmaceuticals has a 52 week low of $8.88 and a 52 week high of $18.93.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).

Read More: Outstanding Shares, Buying and Selling Stocks

Get a free copy of the Zacks research report on Spring Bank Pharmaceuticals (SBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.